Featuring an interview with Ms Charise Gleason, including the following topics:

• Progress and change in the management of multiple myeloma (MM) (0:00)
• Patient- and disease-specific factors guiding therapeutic decision-making for newly diagnosed MM (5:11)
• Role of anti-CD38 antibodies in the management of MM (12:14)
• Emerging treatment options for smoldering myeloma (23:08)
• Optimizing long-term outcomes for patients with MM (25:38)
• Tailoring therapy for older adults and patients with preexisting comorbidities (29:59)
• Case: A woman in her early 80s with newly diagnosed transplant-ineligible MM who experienced a complete response with first-line daratumumab/lenalidomide and low-dose dexamethasone (34:34)
• Case: A man in his early 60s with progressive back pain from standard-risk MM who experienced a complete response with daratumumab with lenalidomide/bortezomib/dexamethasone (42:05)
• Building therapeutic relationships and integrating holistic care in oncology practice (47:13)

NCPD information and select publications